The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

Abstract

BackgroundSecond-line treatment for advanced non-small-cell lung cancer (NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine kinase inhibitor (TKI). These options are the actual standard for EGFR wild-type (WT) status, as patients with EGFR mutations achieve greater benefit by the use of TKI in first-line treatment. Some clinical trials and meta-analyses investigated the comparison between CT and TKI in second-line, but data are conflicting.MethodsWe designed a retrospective trial to gather information about TKI sensitivity in comparison with CT. We selected from clinical records patients treated with at least 1 line of CT and at least 1 line of TKI. We collected data about age, sex, performance status, comorbidity, smoking status, histotype, metastatic sites, EGFR status, treatment schedule, better response and time-to-progression (TTP) for each line of treatment and overall survival (OS).Results93 patients met selection criteria. Mean age 66,7 (range: 46–84). M/F ratio is 3:1. 39 EGFR-WT and 54 EGFR-UK. All patients received erlotinib or gefitinib as second-line treatment or erlotinib as third-line treatment. No TTP differences were observed for both second-line (HR:0,91; p = 0,6333) and third-line (HR:1.1; p = 0,6951) treatment (TKI vs CT). A trend of a benefit in OS in favor of 3rd-line TKI (HR:0,68; p = 0,11).ConclusionsThis study explores the role of TKIs in EGFR non-mutated NSCLC patients. OS analysis highlights a trend to a benefit in patients who received TKI in third-line, even if this result is statistically non-significant. Further analysis are needed to find an explanation for this observation.

An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma

“…In addition, P2Et or P2Et plus aPD-L1 treatment, also induced a high frequency of activated (CD44 + ) CD4 + and CD8 + T cells ( Figure 5D). The assessment of other immune cell populations in the tumor ( Figure 5E) showed that the three treatment strategies decreased the number of MDSC, which due to lack of functional evaluation are called myeloid-derived suppressor like cells (MDSC-LCs) ( Figure 5F) (29). However, the number of tumor-infiltrating monocytic MDSC (M-MDSC) was lower with P2Et plus aPD-L1 treatment compared to P2Et alone ( Figure 5F).…”

Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer

“…The identification of susceptible oncogenic 'drivers' has hastened the development of highly effective drugs. To date these include epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), which target activating mutations in exons 18-21 of the EGFR gene, and anaplastic lymphoma kinase (ALK) inhibitors, which target the echinoderm microtubule associated protein like 4 (EML4)-ALK or c-ros oncogene 1 (ROS1) translocation Bronte et al, 2016). When these oncogenic driver mutations are found in tumour tissue, the efficacy of their respective targeted agents is substantially higher than that of standard chemotherapy.…”

Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

“…Specific mutations of epidermal growth factor receptor (EGFR) play a key role in the development of non-small cell lung cancer (NSCLC), primarily adenocarcinomas, and specific EGFR-targeted therapy has revolutionized the treatment of the subset of adenocarcinomas harboring an EGFR-activating mutation. 1 , 2 …”